BACKGROUND: Interleukin (IL)-1 receptor antagonist (RA) is an anti-inflammatory protein used to treat arthritis that has also been identified as a candidate stroke drug. METHODS: We conducted a systematic review and meta-analysis of reports of the efficacy of IL-1 RA in animal models of focal cerebral ischemia. RESULTS: We identified 16 published sources and one unpublished source of data. IL-1 RA reduced infarct volume by 38.2% (95% confidence interval 31.2%-45.1%). Efficacy was higher with higher doses, earlier treatment, and central administration of drug. No studies used animals with hypertension or diabetes or tested efficacy beyond 3 hours. CONCLUSIONS: The animal data supporting IL-1 RA as a candidate drug for stroke are limited, and further experiments are required before proceeding to clinical trial.
BACKGROUND:Interleukin (IL)-1 receptor antagonist (RA) is an anti-inflammatory protein used to treat arthritis that has also been identified as a candidate stroke drug. METHODS: We conducted a systematic review and meta-analysis of reports of the efficacy of IL-1 RA in animal models of focal cerebral ischemia. RESULTS: We identified 16 published sources and one unpublished source of data. IL-1 RA reduced infarct volume by 38.2% (95% confidence interval 31.2%-45.1%). Efficacy was higher with higher doses, earlier treatment, and central administration of drug. No studies used animals with hypertension or diabetes or tested efficacy beyond 3 hours. CONCLUSIONS: The animal data supporting IL-1 RA as a candidate drug for stroke are limited, and further experiments are required before proceeding to clinical trial.
Authors: Candice M Brown; Cheryl D Bushnell; Gregory P Samsa; Larry B Goldstein; Carol A Colton Journal: Transl Stroke Res Date: 2015-09-15 Impact factor: 6.829
Authors: J Regino Perez-Polo; Harriet C Rea; Kathia M Johnson; Margaret A Parsley; Geda C Unabia; Guojing Xu; Smitha K Infante; Douglas S Dewitt; Claire E Hulsebosch Journal: J Neurotrauma Date: 2013-05-06 Impact factor: 5.269
Authors: Alicia Aliena-Valero; Júlia Baixauli-Martín; María Castelló-Ruiz; Germán Torregrosa; David Hervás; Juan B Salom Journal: J Cereb Blood Flow Metab Date: 2020-11-19 Impact factor: 6.200
Authors: Emily S Sena; H Bart van der Worp; Philip M W Bath; David W Howells; Malcolm R Macleod Journal: PLoS Biol Date: 2010-03-30 Impact factor: 8.029
Authors: H Bart van der Worp; David W Howells; Emily S Sena; Michelle J Porritt; Sarah Rewell; Victoria O'Collins; Malcolm R Macleod Journal: PLoS Med Date: 2010-03-30 Impact factor: 11.069